File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Roles of Methylated DNA Biomarkers in Patients with Colorectal Cancer

TitleRoles of Methylated DNA Biomarkers in Patients with Colorectal Cancer
Authors
Issue Date2019
PublisherHindawi Publishing Corporation. The Journal's web site is located at http://www.hindawi.com/journals/dm/
Citation
Disease Markers, 2019, v. 2019, p. 2673543:1-2673543:8 How to Cite?
AbstractColorectal cancer (CRC) is a leading cancer globally; therefore, early diagnosis and surveillance of this cancer are of paramount importance. Current methods of CRC diagnosis rely heavily on endoscopy or radiological imaging. Noninvasive tests including serum detection of the carcinoembryonic antigen (CEA) and faecal occult blood testing (FOBT) are associated with low sensitivity and specificity, especially at early stages. DNA methylation biomarkers have recently been found to have higher accuracy in CRC detection and enhanced prediction of prognosis and chemotherapy response. The most widely studied biomarker in CRC is methylated septin 9 (SEPT9), which is the only FDA-approved methylation-based biomarker for CRC. Apart from SEPT9, other methylated biomarkers including tachykinin-1 (TAC1), somatostatin (SST), and runt-related transcription factor 3 (RUNX3) have been shown to effectively detect CRC in a multitude of sample types. This review will discuss the performances of various methylated biomarkers used for CRC diagnosis and monitoring, when used alone or in combination.
Persistent Identifierhttp://hdl.handle.net/10722/269343
ISSN
2017 Impact Factor: 2.949
2015 SCImago Journal Rankings: 0.774

 

DC FieldValueLanguage
dc.contributor.authorMa, Z-
dc.contributor.authorWilliams, M-
dc.contributor.authorCheng, YY-
dc.contributor.authorLeung, WK-
dc.date.accessioned2019-04-24T08:05:45Z-
dc.date.available2019-04-24T08:05:45Z-
dc.date.issued2019-
dc.identifier.citationDisease Markers, 2019, v. 2019, p. 2673543:1-2673543:8-
dc.identifier.issn0278-0240-
dc.identifier.urihttp://hdl.handle.net/10722/269343-
dc.description.abstractColorectal cancer (CRC) is a leading cancer globally; therefore, early diagnosis and surveillance of this cancer are of paramount importance. Current methods of CRC diagnosis rely heavily on endoscopy or radiological imaging. Noninvasive tests including serum detection of the carcinoembryonic antigen (CEA) and faecal occult blood testing (FOBT) are associated with low sensitivity and specificity, especially at early stages. DNA methylation biomarkers have recently been found to have higher accuracy in CRC detection and enhanced prediction of prognosis and chemotherapy response. The most widely studied biomarker in CRC is methylated septin 9 (SEPT9), which is the only FDA-approved methylation-based biomarker for CRC. Apart from SEPT9, other methylated biomarkers including tachykinin-1 (TAC1), somatostatin (SST), and runt-related transcription factor 3 (RUNX3) have been shown to effectively detect CRC in a multitude of sample types. This review will discuss the performances of various methylated biomarkers used for CRC diagnosis and monitoring, when used alone or in combination.-
dc.languageeng-
dc.publisherHindawi Publishing Corporation. The Journal's web site is located at http://www.hindawi.com/journals/dm/-
dc.relation.ispartofDisease Markers-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.titleRoles of Methylated DNA Biomarkers in Patients with Colorectal Cancer-
dc.typeArticle-
dc.identifier.emailLeung, WK: waikleung@hku.hk-
dc.identifier.authorityLeung, WK=rp01479-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1155/2019/2673543-
dc.identifier.hkuros297528-
dc.identifier.volume2019-
dc.identifier.spage2673543:1-
dc.identifier.epage2673543:8-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats